Biological quality control and core laboratory considerations for CPET in a clinical trial of ralinepag in patients with pulmonary arterial hypertension: ADVANCE CAPACITY
J. Porszasz (Torrance, United States of America), L. Holdstock (Research Triangle Park, United States of America), S. Blonshine (Mason, United States of America), R. Casaburi (Torrance, United States of America), D. Yehle (Research Triangle Park, United States of America), M. Cunningham (Research Triangle Park, United States of America), J. Blonshine (Mason, United States of America), R. Oudiz (Torrance, United States of America), M. Guazzi (Milan, Italy), F. Torres (Dallas, United States of America), R. Benza (Columbus, United States of America), J. Vachiery (Erasme Academic Hospital, Belgium)
Source: Virtual Congress 2021 – Therapy of pulmonary hypertension
Session: Therapy of pulmonary hypertension
Session type: E-poster
Number: 1931
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Porszasz (Torrance, United States of America), L. Holdstock (Research Triangle Park, United States of America), S. Blonshine (Mason, United States of America), R. Casaburi (Torrance, United States of America), D. Yehle (Research Triangle Park, United States of America), M. Cunningham (Research Triangle Park, United States of America), J. Blonshine (Mason, United States of America), R. Oudiz (Torrance, United States of America), M. Guazzi (Milan, Italy), F. Torres (Dallas, United States of America), R. Benza (Columbus, United States of America), J. Vachiery (Erasme Academic Hospital, Belgium). Biological quality control and core laboratory considerations for CPET in a clinical trial of ralinepag in patients with pulmonary arterial hypertension: ADVANCE CAPACITY. 1931
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: